anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The interplay between metabolic disorders and chronic kidney disease (CKD) has been well-documented. However, the connection between CKD and atherogenic index of plasma (AIP) remains understudied. This research delves into the correlation between these two factors, aiming to shed new light on their potential association.
METHODS: The relationship between AIP and CKD was evaluated using a weighted multivariate logistic regression model, and the curvilinear relationship between AIP and CKD was explored through smooth curve fitting. We engaged a recursive partitioning algorithm in conjunction with a two-stage linear regression model to precisely determine the inflection point. By conducting stratified analyses, the heterogeneity within subpopulations was explored.
RESULTS: In the regression model that accounted for all covariates, ORs (95% CI) for the association between CKD and AIP were 1.12 (0.91, 1.36), indicating no significant association between AIP and CKD. However, sensitivity analyses suggested that the relationship between them may be non-linear. Smooth curve analysis confirmed the non-linear relationship between AIP and CKD, identifying an inflection point at -0.55. Below this threshold, AIP exhibited a significant inverse correlation with CKD. Conversely, above this threshold, a pronounced positive correlation was detected. Stratified analyses elucidated that a non-linear association between AIP and CKD was observed among female participants and those aged 50 and above.
CONCLUSION: We found a curvilinear relationship between chronic kidney disease and atherogenic index of plasma.
<P>PROBLEM TO BE SOLVED: To provide methods and immune modulatory nucleic acid compositions for preventing and treating disease.  <P>SOLUTION: The methods and compositions for treating and preventing disease include the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The method includes a step of administering the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-protein(s), -polypeptide(s) or -peptide(s). The invention also relates to the methods and compositions for treating diseases in a subject associated with one or more self-protein(s), -polypeptide(s) or -peptide(s) which are present in the subject and involved in a non-physiological state.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Patients received only conventional Western medications. And subjects will be assessed on the relevant scales on Day 1 and Day 5 of treatment and will be tested using a near infrared functional brain imaging device before, during and after treatment on that day.
A monitoring hub can monitor a health status of a subject having a wireless wearable device. The monitoring hub can access wireless configuration data received from a remote server. The monitoring can establish wireless communication with the wearable device, based on the wireless configuration data, to wirelessly receive real-time physiological data from the wearable device. The monitoring hub can receive historical physiological data from the remote server. The historical physiological data comprising physiological data collected by the wearable device and/or communicated from the wearable device to another monitoring hub before establishing the wireless communication between the monitoring hub and the wearable device. The monitoring hub can generate user interface data for rendering a user interface including the real-time physiological data in combination with the historical physiological data to reduce a gap in monitoring between the historical physiological data and the real-time physiological data.
As over 15% of pediatric cancers are associated with a cancer predisposition, it is increasingly becoming standard of care for children with cancer, as well as those with suspected hereditary risk, to be evaluated for germline cancer predisposition. Unfortunately, the increase in pediatric genetic testing has exceeded the pace of research establishing best practices to optimize delivery of care for patients undergoing testing and their families. Tumor/normal genetic testing (testing of both tumor tissue and a paired normal sample) at time of cancer diagnosis or relapse is now widespread in pediatric oncology to improve cancer diagnostics, prognostics, and treatment; this testing also has potential to uncover underlying cancer predisposition syndromes with lifelong implications. Disseminating information at the time of cancer diagnosis is difficult, and is best done by a provider with expertise in cancer genetics. Thus, Investigators will develop an informational video for use prior to tumor/normal genetic testing to augment genetic counseling resources to support patients and families.

In this study, Investigators will develop and evaluate the acceptability, feasibility, and preliminary efficacy of an informational video on paired tumor/normal testing for children and adolescents with a new diagnosis of cancer, tumors or other diagnosis. Investigators will use a non randomized trial whereby a convenience sample of patients/families will be recruited to be controls in Year 1, followed by a convenience sample that will be allocated the video intervention In Year 2. To evaluate the impact of the video intervention, Investigators will compare assessments of two cohorts- an unexposed (no video intervention, Year 1) and exposed (video intervention, Year 2).
Postoperative pain after total knee arthroplasty is serious and difficult to management. Multimodal analgesia recommended for the pain management. For these reasons, we planned a study involving two multimodal analgesia regimens. Patients who will undergo total knee arthroplasty will receive preemptive oral analgesic (dexketofrofen) 1 hour before the operation. Surgery will be initiated after spinal anesthesia is applied to the patients. Two pain control methods - the combination of Adductor Canal Block (ACB)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI)/ IPACK- will be applied at the end of the surgery. dexketoprofenand paracetamol will be added to both groups and multimodal analgesia will be applied. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).
A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate Cmax increased by 27% and AUC increased by 29% when hydrochlorothiazide was added to topiramate. The clinical significance of this change is unknown. The addition of hydrochlorothiazide to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of hydrochlorothiazide were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or hydrochlorothiazide administration, which were greater when hydrochlorothiazide and topiramate were administered in combination.
INTRODUCTION: Diarrheal diseases constitute a significant public health problem in terms of mortality and morbidity. In Honduras and around the world, RVs have consistently emerged as the single most important etiologic agent in acute childhood diarrhea. However, other viruses, such as NoVs and HAstVs, have also been shown to be responsible for viral gastroenteritis. Unfortunately, the country has limited information concerning the etiologic role of these viral agents in acute gastroenteritis. This study investigated the frequency, genotypes, and epidemiological characteristics of RV-A, NoVs, and HAstVs among children under 5 years old in Distrito Central, Honduras.
METHODS: Stool samples and their corresponding epidemiological data were collected from children with acute gastroenteritis in three healthcare centers in Distrito Central. All samples were screened by immunoassays for RV-A and HAstVs. RV-A-positive samples were molecularly characterized by RT-PCR and genotyping assays. RT-PCR was also applied to confirm HAstVs positivity and to detect NoVs, followed by nucleotide sequencing to assign their genotypes.
RESULTS: Our results show that at least one viral agent was detected in 31% of the children. The frequency of RV-A, NoVs, and HAstVs was 14%, 13%, and 5%, respectively. The most frequent RV-A genotype was G2P[4], occurring in 93% of cases. 92.3% of NoVs-positive samples belonged to genogroup II, with GII.4 and GII.16 being the most common. HAstVs were clustered into three genotypes: HAstV-1, HAstV-2, and HAstV-8. Only one sample showed coinfection with NoVs and HAstVs.
CONCLUSION: This comprehensive molecular and epidemiological characterization of enteric viruses demonstrates the vast diversity of these agents and describes for the first time NoVs and HAstVs as causative agents of acute childhood gastroenteritis in Distrito Central, Honduras. This suggests that further in-depth studies of the pediatric population are necessary to develop and implement effective preventive and control measures in the country.
The present application relates to the field of immunotherapy, more particularly to the field of chimeric antigen receptors (CARs). Currently, second and third generation CAR designs are quite rigid in that they combine fixed costimulatory domains in cis on the same intracellular protein domain. Trans signaling is not equivalent as costimulatory receptors have different expression levels or stoichiometry. Here, a ‘mix and match’ approach is proposed where different signaling and costimulatory domains are present on separate chains within the same CAR complex, allowing increased flexibility and control of the nature and strength of the CAR-generated signal. Also proposed are polynucleotides, vectors encoding the transmembrane polypeptide chains and cells expressing such CARs. These cells are particularly suitable for use in immunotherapy, and strategies to treat diseases such as cancer using these cells are also provided.
This research aimed to conduct a systematic review of para powerlifting strength performance. The searches were conducted in three electronic databases: PubMed, Scopus, and SPORTDiscus. Intervention studies related to para powerlifting performance were included. The main information was extracted systematically, based on criteria established by the authors. The data on study design, sample size, participant's characteristics (e. g. type of disability, sex, age, body weight, and height), training experience, assessment tools, physical performance criteria, and force-related outcomes were extracted and analyzed. The studies (n=9) describe factors related to biomechanics and performance. Outcomes revealed that the one-repetition maximum test is used as load prescription and that para powerlifting should work at high speeds and higher loads. Regarding technique, grip width with 1.5 biacromial distance provides a good lift and partial amplitude training as an alternative to training. There are no differences in total load and movement quality in the lumbar arched technique compared with the flat technique. As a monitoring method, repetitions in reserve scale was used for submaximal loads. Finally, our outcomes and discussion indicated strategies and techniques that can be used by para powerlifting coaches.
The invention relates to a new conjugate, based on triiodomethane, which also contains at least one natural organic and/or modified natural organic and/or inorganic thickener. Cellulose ethers or starch ethers are particularly suitable for use as the thickener. Said conjugate can be used as a disinfectant and can be introduced into ointments or creams. As a hydrogel containing water and a solvent in addition to the conjugate, with a viscosity of between 5,000 and 400,000 mPa*s (20 ~C), preferably between 10,000 and 30,000 mPa*s (20 ~C), the product is extremely suitable for use as a disinfectant cleaner and hygiene product for cleaning and maintaining animal horn, for example of horses, cattle and sheep. In addition, the hydrogel can contain at least one polyalcohol, in particular glycerine. According to one production method, a hydrogel is produced from water and a thickener and the polyalcohol is first added thereto at a temperature of between 20 and 60 ~C, followed by the solvent containing the triiodomethane.
Approximately twelve healthy adult volunteers with no contraindicated medical conditions or medications will be recruited from CU/Denver and the surrounding community.

Participants will be randomized to one of 2 sequences consisting of two directly observed dosing regimens with 2mg adenine 5+ per dose, 1 dose/week followed by 4 doses/week or 3 doses/week followed by 7 doses/week. Each dose regimen will have a duration of approximately 12 weeks and will be separated by an approximately 12-week washout period for a total study duration of approximately 36 weeks. The rationale for this study design is several fold. First, the lower doses are given initially to minimize the potential effects of carry-over in the second regimen. Second, 1 to 7 doses/week encompass a wide range of simulated adherence rates to assess the promise of this taggant, adenine 5+, as an adherence biomarker. Third, the 12 week duration is designed to achieve \~90% of steady-state given an estimated half-life of 20-30 days.
Twenty patients with possible NCGS on clinical examination and after elimination of CD and AB were included in a study monocentric, randomized, double-blind and crossover design, comparing a gluten-containing diet (RAG) to a gluten-free diet (RSG). The inclusion visit included a specific questioning about digestive and extradigestive symptoms triggered by the consumption of foods with gluten, personal and family history of autoimmune disease, allergy, atopic condition. A dietary consultation made it possible to specify the strict and controlled RSG in FODMAPs (basal diet - RB) to be maintained throughout the 6 weeks of study. After an initial period (PI) of 2 weeks with this RB, patients added for 1 week either foods with gluten (8 g of gluten/d - RAG) or gluten-free foods (RSG) (test periods - PT), the 2 PT being separated by a wash-out period (PWO) of 2 to 3 weeks. Digestive and extradigestive symptoms were assessed by the modified Gastrointestinal Symptom Rating Scale (GSRS) using a 7-point Likert scale (1: absent - 7: very severe), at the end of each week of IP and PWO ( D7 and D14) and every day of each PT. If the symptoms were too severe during PT (i.e. sides of 7), the patient was allowed to stop after a minimum of 72 hours of consumption. For the study of markers of inflammation, immunity, intestinal permeability and metabolomic analyses, blood and urine samples were taken at inclusion and at the end of each PT (or at the end premature). The primary endpoint was the difference in GSRS score at the end of the 2 PTs. Statistical analyzes were carried out using mixed models for a crossover design taking into account subject, diet, period, order and sequence effects and their interactions.
Intermittent claudication is the most common symptom of Peripheral Arterial Disease (PAD) and is associated with decreased quality of life (QoL) due to walking impairment. The level of threat attributed to the disease affects QoL and physical activity. This study explores beliefs and illness drawings, and their relationship with quality of life and physical activity in patients undergoing conservative treatment for PAD. A cross-sectional study was carried out including 119 patients with PAD and Intermittent Claudication, in which patients were asked to freely draw their disease and 33 agreed to participate. The profile of beliefs about PAD is characterized by a low level of threat. Belief in the emotional impact of the disease, representations about the consequences and concern about the disease were associated with worse quality of life; the belief of having a high personal control over the disease was associated with more physical activity. The analysis of the disease drawings revealed three categories: extension of the disease (category 1), location and representations of the disease (category 2), and level of detail and complexity of the drawings (category 3). Greater disease extent was associated with more disease symptoms (IPQ 6) (rs = 0.399, p = .021). It is necessary to address beliefs and representations about the disease in consultations with patients with PAD. Patient drawings are a useful, practical, and free tool that does not require a lot of time and can facilitate the approach of health professionals to patient training and education.
An articulated apparatus is disclosed that includes an actuator base and a plurality of serially coupled link members that are mutually joined to one another at a plurality of joints. Each of the serially coupled link members has an axis of rotation. The plurality of link member includes a proximal link member that is proximal to the actuator base, and a distal link member that is distal to the actuator base, and each link member includes a proximal end and a distal end. The apparatus also includes a plurality of actuators that are located at the base, and each actuator is associated with a respective link member. The apparatus further includes a plurality of tendons, each of which is coupled to an actuator and a respective link member for effecting movement of the link member with respect to the actuator base. At least one tendon is for effecting movement of at least one link member, and passes through the axis of rotation of each joint that is between the distal end of the at least one link member and the actuator base.
Taiwan is already an aging society due to the rapid increase of the aging population. To cope with this situation, it is necessary to make preparations for the care of the elderly. World Health Organization (WHO) proposed aging health strategy in recent years, and the community participation is the most important for the elderly. The courses provided by the community empowering are important to promote the healthy life of the elderly. However, at this stage, there are relatively few courses related to cognitive functions, life-style activities and aging education. It is needed to add more courses related to multi-domain.

Investigators anticipate recruiting a total of 50 participants with cognitive decline. The participants will receive a total of 12 training sessions, and each session will contain 120 minutes of training. The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. Investigators plan to assess the participants before and after the intervention programs. Investigators expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
The intervention group (n = 30) will receive Routine Hospital Management (RHM), conventional rehabilitation activity and AT (painting, coloring, listening to music and Hand Therapy Ball Exercises). Overall 9 sessions over a period of three weeks will be performed and each session will take around 30 min.
Eligible infants will be approached by study team. Parents whose infants consent to the study drug will enter the dose-escalation part of the study. Inhaled Alvesco will be administered daily for 14 days at escalating doses 80mcg, 160mcg and 320mcg.
Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
The invention provides an application of an agent for silencing or inhibiting LPCAT1 gene in inducing iron death of tumor cells. The present invention found that LPCAT1 plays a key role in iron death resistance by increasing membrane phospholipid saturation through Lands cycle, decreasing polyunsaturated fatty acid levels on cell membranes, thereby protecting cells from membrane damage caused by phospholipid peroxidation and inhibiting iron death. Thus, agents that silence or inhibit the LPCAT1 gene can induce iron death in cells, thereby acting as an inducer of iron death in cells. Furthermore, enhancement of the tumor cell's in vivo tumorigenicity is closely related to the upregulation of LPCAT1 and the emergence of iron death resistance. Iron death inducers in combination with LPCAT1 inhibition synergistically trigger iron death and inhibit tumor growth, thereby treating tumors. The invention shows that the membrane phospholipid remodelling mediated by the LPCAT1 promotes the iron death escape by increasing the phospholipid saturation, reveals the important role of the LPCAT1 in the iron death escape, and provides a new target and strategy for tumor treatment of targeting iron death.
Inventors have shown that CD70 and CD27 are highly expressed in ccRCC and correlates with poor survival. Multiplex IF demonstrated that CD27+ T cells interact with CD70+ tumor cells in tumor microenvironment (TME). CD27+ T cells are more apoptotic than CD27- T cells in ccRCC. Elevated levels of plasma sCD27 is observed in ccRCC patients and correlates with CD27-CD70 interaction  in situ . Their study demonstrates that CD27-CD70 interaction contributes to the release of sCD27 in peripheral blood in ccRCC, indicating that sCD27 is a potential biomarker. The apoptosis of CD27+T cells suggests the deleterious effect of CD27-CD70 interaction in T cell response. Therefore, CD27/CD70 is a promising therapeutic target in ccRCC. Accordingly, the invention relates to a method for determining the interaction between CD27 and CD70 by determining the level of soluble CD27 (sCD27) in a biological sample and to method of targeting CD27/CD70 interaction to treat a cancer or metastatic cancer.
PURPOSE:To obtain the title adhesive consisting of the first mixed liquid of polymerizable monomer containing a reducing agent and photosensitizer and the second mixed liquid of polymerizable monomer containing an organic peroxide and/or photosensitizer and having extremely excellent workability as well as excellent bond strength. CONSTITUTION:The title adhesive consisting of the first mixed liquid of polymerizable monomer containing a reducing agent (e.g. tert. amine, sulfinic acid, aralkylbarbituric acid) and photosensitizer (e.g. camphorquinone or benzil) and the second mixed liquid of polymerizable monomer containing an organic peroxide (e.g. benzoyl peroxide) and/or photosensitizer. The typical polymerizable monomer includes (meth)acrylic acid ester (e.g. methyl methacrylate). When the above-mentioned adhesive is inserted between a base face and tooth face of bracket for correcting tooth having light transmission properties, prescribed bond strength is obtained by short-term light irradiation and time causing pain by opening of mouth to a patient can be shortened.